---
title: "Biogen Inc. (BIIB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BIIB.US.md"
symbol: "BIIB.US"
name: "Biogen Inc."
industry: "Biotechnology"
datetime: "2026-05-19T14:08:30.126Z"
locales:
  - [en](https://longbridge.com/en/quote/BIIB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BIIB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BIIB.US.md)
---

# Biogen Inc. (BIIB.US)

## Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.biogen.com](https://www.biogen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 68 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.23% |  |
| Net Profit YoY | -7.26% |  |
| P/B Ratio | 1.52 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 28333039123.47 |  |
| Revenue | 9937400000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.70% | B |
| Profit Margin | 13.81% | B |
| Gross Margin | 75.37% | A |
| Revenue YoY | 1.23% | C |
| Net Profit YoY | -7.26% | C |
| Total Assets YoY | 5.17% | C |
| Net Assets YoY | 9.85% | B |
| Cash Flow Margin | 188.85% | B |
| OCF YoY | 1.23% | C |
| Turnover | 0.35 | D |
| Gearing Ratio | 36.74% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Biogen Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.23%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-7.26%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.52",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "28333039123.47",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "9937400000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.70%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "13.81%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "75.37%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.23%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-7.26%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.17%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.85%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "188.85%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1.23%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "36.74%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 20.65 | 37/386 | 20.60 | 15.02 | 13.06 |
| PB | 1.52 | 141/386 | 1.48 | 1.33 | 1.13 |
| PS (TTM) | 2.85 | 68/386 | 2.72 | 2.40 | 1.98 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **36**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 18 | 50% |
| Overweight | 2 | 6% |
| Hold | 15 | 42% |
| Sell | 1 | 3% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 190.18 |
| Highest Target | 275.00 |
| Lowest Target | 150.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BIIB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BIIB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BIIB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BIIB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**